Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03680794 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 1, 2024 to Dec 27, 2027
    • Study completion date: Feb 1, 2025 to Feb 27, 2028
    v4
  2. Primary completion date: Dec 1, 2021 to Dec 1, 2024
    • Study completion date: Feb 1, 2022 to Feb 1, 2025
    v3
  3. Primary completion date: Sep 1, 2019 to Dec 1, 2021
    • Start date: May 2, 2018 to Jun 27, 2018
    • Study completion date: Jan 1, 2020 to Feb 1, 2022
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CHU de Reims
79 trials monitored
See 2 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test. The investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.
Trial Details
NCT Number NCT03680794
Lead Sponsor CHU de Reims
Conditions
(from sponsor)		 Diabetic Retinopathy, Retinal Vein Occlusion
Related terms Diabetic Retinopathy, Retinal Vein Occlusion
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov